RUNX2 and prostate carcinoma: A comprehensive study by Akech et al. [148] demonstrated that overexpression of RUNX2 in prostate cancer cells inoculated into bone led to activation of genes necessary for osteolytic disease, PTH-related protein (PTHrP) and interleukin 8 (IL8).